Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Non-metastatic, Hormone naïve Prostate Cancer 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Adenocarcinoma of the Prostate 1

Interventions

Docetaxel 2Androgen Antagonists 2darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Metastatic Hormone-sensitive Prostate Cancer × Androgen Antagonists × Clear all
NCT00309985 2025-12-11

CHAARTED

Eastern Cooperative Oncology Group

Phase 3 Completed
790 enrolled 11 charts
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT02799602 2025-12-04

ARASENS

Bayer

Phase 3 Completed
1,306 enrolled 25 charts 2 FDA
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡